PubRank

E Olah

Author PubWeight™ 57.65‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003 18.67
2 The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 2008 3.87
3 Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 2005 1.91
4 Somatic mutations of KIT in familial testicular germ cell tumours. Br J Cancer 2004 1.64
5 Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet 1998 1.61
6 Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 2000 1.51
7 Emerging roles of BRCA1 alternative splicing. Mol Pathol 2003 1.41
8 The future of primary paediatric care in Europe: reflections and Report of the EPA/UNEPSA Committee. Acta Paediatr 2010 1.40
9 Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. Biochem Biophys Res Commun 2001 1.20
10 High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999 1.19
11 Purifying selection on silent sites -- a constraint from splicing regulation? Trends Genet 2001 1.18
12 Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer. Am J Hum Genet 1997 1.16
13 Consortium study on 1280 breast carcinomas: allelic loss on chromosome 17 targets subregions associated with family history and clinical parameters. Cancer Res 1998 1.12
14 Strong founder effects in BRCA1 mutation carrier breast cancer patients from Latvia. Mutation in brief no. 258. Online. Hum Mutat 1999 1.11
15 Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland. Hum Mutat 2000 1.03
16 Germline mutation analysis of BRCA1 and BRCA2 genes in Yugoslav breast/ovarian cancer families. Oncol Rep 1999 0.98
17 Molecular mechanisms in the antiproliferative action of quercetin. Life Sci 1997 0.98
18 Constitutive intracellular expression and activation-induced cell surface up-regulation of CD44v3 in human T lymphocytes. Eur J Immunol 2001 0.91
19 Quercetin down-regulates signal transduction in human breast carcinoma cells. Biochem Biophys Res Commun 1995 0.88
20 Loss of heterozygosity at 11q23.1 and survival in breast cancer: results of a large European study. Breast Cancer Somatic Genetics Consortium. Genes Chromosomes Cancer 1999 0.87
21 Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). J Biol Chem 1984 0.86
22 Insurance implications for individuals with a high risk of breast and ovarian cancer in Europe. Dis Markers 1999 0.86
23 Biochemical commitment to replication in cancer cells. Adv Enzyme Regul 1980 0.85
24 Dynamics of modulation of biochemical programs in cancer cells. Adv Enzyme Regul 1980 0.84
25 A breast/ovarian cancer patient with germline mutations in both BRCA1 and BRCA2. Nat Genet 1997 0.84
26 Phase and cell cycle specificity of pyrazofurin action. Cancer Res 1980 0.83
27 Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin. Adv Enzyme Regul 1989 0.82
28 Effects of cytostatics on proliferating and stationary cultures of mammalian cells. Eur J Cancer 1978 0.81
29 Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas. Br J Cancer 1996 0.80
30 Colon tumor: enzymology of the neoplastic program. Life Sci 1978 0.80
31 Giemsa-banding karyotype of rat hepatomas of different growth rates. Cancer Res 1979 0.80
32 Biochemical programs and enzyme-pattern-targeted chemotherapy in cancer cells. Adv Enzyme Regul 1978 0.79
33 Sequence alterations can mask each other's presence during screening with SSCP or heteroduplex analysis: BRCA genes as examples. Biotechniques 2000 0.79
34 European multicenter study on LOH of APOC3 at 11q23 in 766 breast cancer patients: relation to clinical variables. Breast Cancer Somatic Genetics Consortium. Br J Cancer 1999 0.77
35 Regulation of the signal transduction program by drugs. Adv Enzyme Regul 1997 0.77
36 Significance of purine salvage in circumventing the action of antimetabolites in rat hepatoma cells. Cancer Res 1989 0.77
37 Linkage of reduction in 1-phosphatidylinositol 4-kinase activity and inositol 1,4,5-trisphosphate concentration in human ovarian carcinoma cells treated with quercetin. Life Sci 1995 0.76
38 AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells. Cancer Commun 1991 0.76
39 Aggressive infantile myofibromatosis: report of a case of a clinically progressive congenital multiple fibromatosis. Med Pediatr Oncol 1986 0.75
40 Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas. Gynecol Oncol 1992 0.75
41 Synergistic action of taxol with tiazofurin and methotrexate in human breast cancer cells: schedule-dependence. Life Sci 1994 0.75
42 Biochemistry of cycling and resting cancer cells. Prog Clin Biol Res 1983 0.75
43 Action of lycurim and pyrazofurin on hepatoma 3924A cells in culture. Cancer Treat Rep 1982 0.75
44 Allele loss of tumour suppressor genes on chromosome 17 in human testicular germ cell tumours. Int J Oncol 1996 0.75
45 Utilization of dietary urea in rainbow trout. Ann Nutr Metab 1983 0.75
46 Cytotoxic and cell kinetic effects of 3,4,5-trihydroxybenzohydroxamic acid (VF 122) in hepatoma 3924A cells. Cancer Treat Rep 1982 0.75